Back to Awarded Treatment Trials
Awarded Trial: 00-225
Grant ID
00-225
Illness
Schizophrenia
Primary Drug/Intervention
Olanzapine
Primary Dosage
open dose titration
Secondary Drug Intervention
Haloperidol
Secondary Dosage
Open dose titration
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Rosebush
Sample Size
124
Duration of Study Period for Each Subject
4 weeks, with long term follow-up of up to 6 years
Outcome Measurements
BPRS, GAF, HAM-D, HAM-A, YMRS, CGI, PANSS, Movement Disorder Scale
Results
One hundred twenty four patients were included in the study. Sixty-three were randomized to olanzapine and 61 were randomized to haloperidol. There was a slight benefit of haloperidol over olanzapine at weeks 1 and 2 for BPRS scores. There was also a slight advantage of haloperidol over olanzapine at week 1 for the HAM-D scale. The other rating scales did not show significant differences. Significantly more patients receiving haloperidol developed Parkinsonism compound to patients receiving olanzapine, but there was no difference between groups for dystonia, akathisia or tardive dyskinesia.
Publication
N/A
Link
N/A
PI Name
Patricia Rosebush
Degree
MD
Center
N/A
Institution
McMaster University
Address
1200 Main Street, HSC-3G15
City or Town
Hamilton
State or Province
Ontario
Zip or Postal Code
ON L8N 3Z5
Country
Canada
Email Address
rosebush@hhsc.ca